# A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct01991795` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01991795](<https://clinicaltrials.gov/study/NCT01991795>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01991795

Browse, organ or system: Heart; Metabolism  
Browse, condition area: Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 19271 participants.

## Technical summary

Registry record NCT01991795. Randomized; quadruple masking; primary purpose prevention. Start 2014-02-10 (actual); primary completion 2019-01-25 (actual). Results posted on 2020-03-18.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 19271 participants (enrolled count; ClinicalTrials.gov record NCT01991795, source copy `cardio:ctgov-nct01991795-2020-03-18`, retrieved 2026-10-26)
- Started: 2014-02-10 (actual) (ClinicalTrials.gov record NCT01991795, source copy `cardio:ctgov-nct01991795-2020-03-18`, retrieved 2026-10-26)
- Primary completion: 2019-01-25 (actual) (ClinicalTrials.gov record NCT01991795, source copy `cardio:ctgov-nct01991795-2020-03-18`, retrieved 2026-10-26)
- Completion: 2019-01-25 (actual) (ClinicalTrials.gov record NCT01991795, source copy `cardio:ctgov-nct01991795-2020-03-18`, retrieved 2026-10-26)
- Results first posted: 2020-03-18 (ClinicalTrials.gov record NCT01991795, source copy `cardio:ctgov-nct01991795-2020-03-18`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Czechia; Denmark; Finland; France; Germany; Hong Kong SAR China; Hungary; India; Israel; Italy; Japan; Mexico; Netherlands; Norway; Peru; Philippines; Poland; Puerto Rico; Romania; Russia; Saudi Arabia; Slovakia; South Africa; South Korea; Spain; Sweden; Taiwan; Thailand; Türkiye; Ukraine; United Kingdom; Vietnam (ClinicalTrials.gov record NCT01991795, source copy `cardio:ctgov-nct01991795-2020-03-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01991795-2020-03-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus
- Acronym: THEMIS
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Ticagrelor 60 mg
- Intervention (Drug): Ticagrelor placebo
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Ticagrelor (`cardio:ticagrelor`)
- Registry intervention is a member of this class by a sourced record link: P2Y12 inhibitors (drug class) (`cardio:p2y12-inhibitors`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and Atherosclerosis (`cardio:pubmed-38658101`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: e4f0fe4157a45848550bd044a9a0ae8d96868fccf589d0f893b85f897e07e8a2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
